From the article:
"Scores with the 22-gene Decipher genomic classifier (GC) were independently associated with risk for metastasis, prostate cancer-specific mortality, and overall survival among men with recurrent prostate cancer treated with salvage radiotherapy with or without bicalutamide."
"These results suggest that not all men with biochemically recurrent disease after surgery will benefit from hormone therapy, reported Felix Y. Feng, MD, of the University of California San Francisco, and colleagues in JAMA Oncology." (emphasis added.)
Article is here:
medpagetoday.com/hematology...
And for those with a JAMA account, an accompanying editorial by Sean E. McGuire, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, is here:
jamanetwork.com/journals/ja...
Required reading, as Decipher may be a critical new tool in making effective treatment decisions.
Stay Well - K9